Headache and Migraine

Limitations of current pain scales used by health care professionals who manage patients with migraine, and considerations for using patient diaries to help monitor symptoms and recommend appropriate therapy.

An overview regarding the various phases of migraine and recommendations for using empowering language when educating patients on what to expect from attacks.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Elyse Stock, MD, and Thomas Shiovitz, MD.

A recent review outlined the clinical features, pathophysiology, and treatments for cluster headache, finding noninvasive vagus nerve stimulation to be effective in various ways.

Current hurdles faced by neurologists when prescribing therapy to treat migraine and advice to help other healthcare professionals as well as patients navigate insurance and access issues.

A patient advocate, Jill Dehlin, RN, explains why patients with migraine should connect with other patients via patient support programs and take a proactive role in managing their condition.

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 30, 2021.

Examples of migraine advocacy as it pertains to health care professionals and advice for clinicians who manage patients with migraine to help address the stigma often associated with the condition.  

Amaal J. Starling, MD, of Mayo Clinic, expresses how common and disabling migraine is on patients and comments on the stigma associated with the condition.

"Mind Moments," a podcast from NeurologyLive, brings you exclusive interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD.

The director at AbbVie discussed a subgroup analysis of the phase 3 ADVANCE study of atogepant in patients with migraine and its benefit on patient-reported outcome measures.

Advice to community neurologists and other care providers who may treat patients with migraine in the community setting on incorporating newer therapies, such as CGRP inhibitors, into practice, and a list of reputable resources where patients can turn for additional support.

Jill Dehlin, RN, describes her role as an advocate in supporting others with migraine and connecting them to the support and resources needed to best manage their condition.

The director of the MedStar Georgetown Headache Center spoke to the considerations she makes in determining when patients with migraine may need a nonoral therapy to address their disease.

The director of the MedStar Georgetown Headache Center spoke to the efficacy and application of a new formulation of the longstanding agent dihydroergotamine in the treatment of migraine.

In addition to a number of positive attributes stemming from telehealth use, most providers claimed they were interested in digitally prescribing headache apps and remotely monitoring patient symptoms.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending April 24, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 23, 2021.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the reasons fremanezumab stands out among a crowded migraine treatment landscape.

The director at AbbVie discussed a number of abstracts presented at AAN 2021 involving atogepant and its phase 3 ADVANCE study.

The potential connection between risk of dementia in patients treated with triptans for migraine as compared to the safety profiles of newer CGRP monoclonal antibodies.

Jessica Ailani, MD, of MedStar Health, describes the mechanisms of action and indications for use of currently available CGRP inhibitors for migraine.